Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel C Chambers

Showing results (71-80 of 74) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 74 results.
Nature Communications|September 17, 2020
Translational pharmacology of an inhaled small molecule αvβ6 integrin inhibitor for idiopathic pulmonary fibrosisAlison E John, Rebecca H Graves, K Tao Pun, et al.
BMJ Open Respiratory Research|September 24, 2021
Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID)Jim M Wild, Joanna C Porter, Philip L Molyneaux, et al.
Ebiomedicine|January 25, 2026
Residual lung abnormality following COVID-19 hospitalisation is characterised by biomarkers of epithelial injuryIain Stewart, Joseph Jacob, Joanna C Porter, et al.
American Journal of Respiratory and Critical Care Medicine|December 2, 2022
Residual Lung Abnormalities after COVID-19 Hospitalization: Interim Analysis of the UKILD Post-COVID-19 StudyIain Stewart, Joseph Jacob, Peter M George, et al.
Pageof 8

Showing results (71-80 of 74) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 74 results.
Nature Communications|September 17, 2020
Translational pharmacology of an inhaled small molecule αvβ6 integrin inhibitor for idiopathic pulmonary fibrosisAlison E John, Rebecca H Graves, K Tao Pun, et al.
BMJ Open Respiratory Research|September 24, 2021
Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID)Jim M Wild, Joanna C Porter, Philip L Molyneaux, et al.
Ebiomedicine|January 25, 2026
Residual lung abnormality following COVID-19 hospitalisation is characterised by biomarkers of epithelial injuryIain Stewart, Joseph Jacob, Joanna C Porter, et al.
American Journal of Respiratory and Critical Care Medicine|December 2, 2022
Residual Lung Abnormalities after COVID-19 Hospitalization: Interim Analysis of the UKILD Post-COVID-19 StudyIain Stewart, Joseph Jacob, Peter M George, et al.
Pageof 8